SCHEMBL25589902

SCHEMBL25589902

CC(C)NC12CC3CC(C1)CC(OC(=O)NC(C)(C)C)(C3)C2

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 10/20 0.53
DPP9 Q86TI2 10/20 0.53
DPP4 P27487 4/20 0.53
GLMN Q92990 1/20 0.36
DYRK3 O43781 1/20 0.36
CSNK1E P49674 1/20 0.36
CLK1 P49759 1/20 0.36
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
DYRK2 Q92630 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
DYRK4 Q9NR20 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
CACNA1H O95180 1/20 0.35
MEN1 O00255 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3363251 0.78 DPP8 (0.48) DPP8DPP9DPP4DYRK3CSNK1E
SCHEMBL28760791 0.76 DPP8 (0.57) DPP8DPP9DPP4GLMNDYRK3
SCHEMBL25589739 0.74 DPP4 (0.38) DPP4
SCHEMBL6382523 0.70 DPP4 (1.00) DPP8DPP9DPP4
SCHEMBL30684999 0.70 DPP8 (1.00) DPP8DPP9GLMN
SCHEMBL25210640 0.70 DPP8 (0.43) DPP8DPP9DPP4DYRK3CSNK1E
SCHEMBL25589920 0.68 TSHR (0.44) KMT2A
SCHEMBL25736741 0.68 MEN1 (0.45) DPP8DPP9DPP4GLMNCACNA1H
SCHEMBL25589905 0.67 GRIN2D (0.35) DPP8DPP9DPP4
SCHEMBL5608925 0.67 THRB (0.42) DPP8DPP9DPP4GLMN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 CLK1, CLK2, CLK3 DPP8 3622/4885DPP9 3331/4885DPP4 4149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.